Musings from The Power List: Dajun Yang
The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics
Clinical Scorecard: Musings from The Power List: Dajun Yang
At a Glance
| Category | Detail |
|---|
| Condition | Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma |
| Key Mechanisms | Targeting apoptotic pathways and protein degradation |
| Target Population | Patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who have received prior systemic therapy |
| Care Setting | Biopharmaceutical development and commercialization |
Key Highlights
- Approval of lisaftoclax in China for chronic lymphocytic leukemia in July 2025
- Olverembatinib approved in China for chronic myeloid leukemia
- Emergence of protein degraders like proteolysis-targeting chimeras
- Oral bioavailability of small molecules enhances patient quality of life
- Advancements in targeted protein degradation technology
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with chronic lymphocytic leukemia and chronic myeloid leukemia
Oral administration of approved therapies improves adherence and quality of life
Clinical Best Practices
- Consider the unique advantages of small molecules in treatment plans
- Monitor advancements in protein degradation therapies
- Evaluate the evolving landscape of drug modalities in patient care
Related Resources & Content
